The company consists of Life Science Research Center, New Drug Pilot Research Center and New Drug Quality Research Center.
Newsummit Biopharma
Newsummit positions itself as a CRO+ organization i.e. a CRO service provider with project-based investment function. The Company not only provides professional CRO (Contract Research Organization) services, but also invests in and conducts joint biopharmaceutical R&D projects with its collaboration partners.
NewSummit Biopharma is an innovative biopharmaceutical R&D group consisting of following member companies:
The Delaware US-based Newsummit Holding Company
Shanghai Newsummit Biopharma R&D Co Ltd
Shanghai Newsummit Biopharma Co Ltd
Shanghai Urban Newsummit Pharma Co Ltd
Dalian Newsummit Biophama Technology Services Co Ltd
Newsummit is currently seeking public listing on the NASAQ, which will help the Company launch an international biopharmaceutical R&D services platform aiming at a global outreach.
It accelerates new drug development process by providing highly efficient and cost-effective technology services in candidate protein expression optimization, process development for pilot- and industry-scale production, pre-clinical and clinical (Phase I - IV) studies and the ensuing regulatory filings with SFDA i.e. IND and NDA. In addition, it has also adopted a risk-sharing co-development collaboration model by co-investing in projects with promising market potentials in China, bringing flexibilities to cash-strapped industry customers, in particular start-up companies.